Natalie Bellini, DNP, FNP-BC, is a nurse practitioner specializing in diabetes management with the R&B Medical Group based out of Niagara Falls, NY. 

Natalie Bellini, DNP, FNP-BC

For diabetes care and education specialists, late April and early May have ushered in a whirlwind of knowledge and advances. ATTD 2022 marked the start of a conference season that includes meetings hosted by the American Association of Clinical Endocrinology (AACE), the American Diabetes Association (ADA), and the Endocrine Society within a 48-day span. Add to this, news surrounding the US FDA’s 

approval of Eli Lilly and Company’s novel dual GIP/GLP-1 receptor agonist

, tirzepatide, and the full docket of news and information to download from this brief period becomes clear.

In this episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the tirzepatide approval, including discussions around the mechanism of action for the first-in-class agent, dose titrations, and where it might fit in the upcoming ADA standards of care. Later in the episode, hosts recap their experiences from 

, which saw the release of guidelines for diagnosis and management of nonalcoholic fatty liver disease (NAFLD) in primary care and endocrinology clinical settings.

previous episodes of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

recap of the 15th International Conference on Advanced Technologies and Treatments for Diabetes.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives is available in an audio-only format on 

Podcasts

In this episode of Diabetes Dialogue, hosts Drs. Isaacs and Bellini take a deep dive into the tirzepatide approval, including discussions around the mechanism of action, dose titrations, and where it might fit in the upcoming ADA standards of care. Later in the episode, hosts recap their experiences from AACE 2022, which saw the release of new guidelines for NAFLD.

Diabetes Dialogue: Tirzepatide in Action & AACE 2022 Recap

In this special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, recap their experiences from the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD). 

Topics of discussion for the episode include favorite sessions from the conference and clinical pearls they took away from their experience, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems. Also included in the episode is a reaction to Eli Lilly and Company’s announcement of topline data from the SURMOUNT-1 trial in late April.

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on 

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini provide insight from ATTD 2022, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems. 

Diabetes Dialogue: ATTD 2022 Recap

The history of diabetes management is one characterized by tremendous advances that have transformed care and life expectancies of patients dating back to the discovery of insulin more than 100 years ago.

Since 1921, the diabetes care team has been the beneficiary of a multitude of other noteworthy advancements, with many of the most recent coming as a result of heightened technology finding a role in management. If there were any drawbacks to the rapid rate of advancement in diabetes technology in the last 20 years, it would be the difficulty in keeping up with the sheer amount of data related to these newer technologies.

With this in mind, Endocrinology Network is proud to introduce its latest multimedia offering, “Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives”. Hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, the monthly podcast is aimed at providing listeners with insight from their real-world experiences on how to best leverage advances in therapeutics and technology to improve diabetes management. 

In the first episode, Isaacs and Bellini offer guests insight into their backgrounds and expertise as well as recap recent regulatory news from the first 3 months of 2022 impacting diabetes specialists, including the Eversense 180-day CGM, Dexcom G7’s CE Mark in Europe, and more.

The inaugural episode of Diabetes Dialogue features an introduction to hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, and a discussion around recent regulatory news surrounding CGM devices in the US and Europe. 

Natalie Bellini, DNP, FNP-BC

Articles

Diabetes Dialogue: Tirzepatide in Action & AACE 2022 Recap

Diabetes Dialogue: ATTD 2022 Recap

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives